We use cookies to understand how you use our site and to improve your experience.
This includes personalizing content and advertising.
By pressing "Accept All" or closing out of this banner, you consent to the use of all cookies and similar technologies and the sharing of information they collect with third parties.
You can reject marketing cookies by pressing "Deny Optional," but we still use essential, performance, and functional cookies.
In addition, whether you "Accept All," Deny Optional," click the X or otherwise continue to use the site, you accept our Privacy Policy and Terms of Service, revised from time to time.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
SNY Stock Down on Double Trouble With Multiple Sclerosis Drug
Read MoreHide Full Article
Key Takeaways
SNY stock fell nearly 2% after two setbacks tied to Sanofi's investigational MS drug tolebrutinib.
The FDA pushed its decision on tolebrutinib for nrSPMS to the first quarter of 2026 after new submissions.
SNY said tolebrutinib failed the primary endpoint in a phase III PPMS study, ending development in that use.
Shares of Sanofi (SNY - Free Report) fell nearly 2% on Monday after the company reported two setbacks in connection with its investigational multiple sclerosis (MS) drug, tolebrutinib.
FDA Delays Decision on SNY’s MS Drug Again
Sanofi announced that the FDA has extended the regulatory review of its filing seeking approval to treat non-relapsing secondary progressive MS (nrSPMS) and slow disability accumulation independent of relapse activity in adults.
This is the second time that the agency has extended its review period. The FDA was initially expected to give its decision by Sept. 28, 2025. However, this date was extended by an additional three months to Dec. 28 after Sanofi’s submission of additional analyses during the review process, which the agency deemed a major amendment to the original filing. The agency once again revised this date after the company submitted an expanded access protocol for the drug in nrSPMS, at the FDA’s request.
A final decision is now expected in the first quarter of 2026. A similar filing is also currently under review in the European Union.
SNY’s Tolebrutinib Also Faces Clinical Setback
In a separate press release, Sanofi announced that it did not meet the primary endpoint in the phase III PERCEUS study, which evaluated tolebrutinib in patients with primary progressive MS (PPMS). While the company did not share any numbers, it noted that the safety profile was consistent with previously conducted studies on the drug.
Based on this setback, Sanofi has decided not to pursue further development in PPMS — an area that represents 10% of the overall MS patient population. Still, the company plans to report full safety and efficacy results from this study at a future medical meeting.
MS is a chronic neurodegenerative disease that causes disability accumulation over time, which is not properly addressed by the currently available therapies that are designed to primarily address peripheral inflammation.
SNY’s Stock Performance
Post the two back-to-back announcements on tolebrutinib, investors began raising concerns about the company’s future. Many investors have been viewing the drug as one of the company’s first attempts to diversify its top line, which is currently dependent on Dupixent for growth prospects.
Though Sanofi still upheld the risk-benefit profile of tolebrutinib for nrSPMS, investors did not seem to reciprocate the same feeling. This difference of opinion was likely the reason for the sell-off in the company’s share price on Monday.
Year to date, the stock has declined 1% against the industry’s 16% growth.
Image Source: Zacks Investment Research
More on SNY's Tolebrutinib
This is not the first time that Sanofi has faced a setback with tolebrutinib. In 2022, the FDA placed a partial clinical hold on Sanofi’s phase III studies on tolebrutinib in MS and myasthenia gravis (MG) indications after the regulatory agency identified cases of drug-induced liver injury in some study participants who were treated with the drug.
The MG studies on tolebrutinib were eventually discontinued in 2022 after careful evaluation of the emerging competitive treatment landscape.
Tolebrutinib was added to Sanofi’s portfolio with the acquisition of Principia in 2020.
In the past 60 days, estimates for ANI Pharmaceuticals’ 2025 earnings per share (EPS) have risen from $7.29 to $7.56. EPS estimates for 2026 have increased from $7.81 to $8.08 during the same period. Year to date, shares of ANIP have surged over 47%.
ANIP’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 21.24%.
Estimates for CorMedix’s 2025 EPS have increased from $1.85 to $2.87 over the past 60 days, while the same for 2026 has increased from $2.49 to $2.88. CRMD shares have risen 42% year to date.
CorMedix’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 27.04%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
SNY Stock Down on Double Trouble With Multiple Sclerosis Drug
Key Takeaways
Shares of Sanofi (SNY - Free Report) fell nearly 2% on Monday after the company reported two setbacks in connection with its investigational multiple sclerosis (MS) drug, tolebrutinib.
FDA Delays Decision on SNY’s MS Drug Again
Sanofi announced that the FDA has extended the regulatory review of its filing seeking approval to treat non-relapsing secondary progressive MS (nrSPMS) and slow disability accumulation independent of relapse activity in adults.
This is the second time that the agency has extended its review period. The FDA was initially expected to give its decision by Sept. 28, 2025. However, this date was extended by an additional three months to Dec. 28 after Sanofi’s submission of additional analyses during the review process, which the agency deemed a major amendment to the original filing. The agency once again revised this date after the company submitted an expanded access protocol for the drug in nrSPMS, at the FDA’s request.
A final decision is now expected in the first quarter of 2026. A similar filing is also currently under review in the European Union.
SNY’s Tolebrutinib Also Faces Clinical Setback
In a separate press release, Sanofi announced that it did not meet the primary endpoint in the phase III PERCEUS study, which evaluated tolebrutinib in patients with primary progressive MS (PPMS). While the company did not share any numbers, it noted that the safety profile was consistent with previously conducted studies on the drug.
Based on this setback, Sanofi has decided not to pursue further development in PPMS — an area that represents 10% of the overall MS patient population. Still, the company plans to report full safety and efficacy results from this study at a future medical meeting.
MS is a chronic neurodegenerative disease that causes disability accumulation over time, which is not properly addressed by the currently available therapies that are designed to primarily address peripheral inflammation.
SNY’s Stock Performance
Post the two back-to-back announcements on tolebrutinib, investors began raising concerns about the company’s future. Many investors have been viewing the drug as one of the company’s first attempts to diversify its top line, which is currently dependent on Dupixent for growth prospects.
Though Sanofi still upheld the risk-benefit profile of tolebrutinib for nrSPMS, investors did not seem to reciprocate the same feeling. This difference of opinion was likely the reason for the sell-off in the company’s share price on Monday.
Year to date, the stock has declined 1% against the industry’s 16% growth.
Image Source: Zacks Investment Research
More on SNY's Tolebrutinib
This is not the first time that Sanofi has faced a setback with tolebrutinib. In 2022, the FDA placed a partial clinical hold on Sanofi’s phase III studies on tolebrutinib in MS and myasthenia gravis (MG) indications after the regulatory agency identified cases of drug-induced liver injury in some study participants who were treated with the drug.
The MG studies on tolebrutinib were eventually discontinued in 2022 after careful evaluation of the emerging competitive treatment landscape.
Tolebrutinib was added to Sanofi’s portfolio with the acquisition of Principia in 2020.
SNY’s Zacks Rank
Sanofi currently carries a Zacks Rank #3 (Hold).
Sanofi Price
Sanofi price | Sanofi Quote
Key Picks Among Biotech Stocks
Some better-ranked stocks from the sector are ANI Pharmaceuticals (ANIP - Free Report) and CorMedix (CRMD - Free Report) , each sporting a Zacks Rank #1 (Strong Buy) at present. You can see the complete list of today’s Zacks #1 Rank stocks here.
In the past 60 days, estimates for ANI Pharmaceuticals’ 2025 earnings per share (EPS) have risen from $7.29 to $7.56. EPS estimates for 2026 have increased from $7.81 to $8.08 during the same period. Year to date, shares of ANIP have surged over 47%.
ANIP’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 21.24%.
Estimates for CorMedix’s 2025 EPS have increased from $1.85 to $2.87 over the past 60 days, while the same for 2026 has increased from $2.49 to $2.88. CRMD shares have risen 42% year to date.
CorMedix’s earnings beat estimates in each of the trailing four quarters, delivering an average surprise of 27.04%.